Business Context and Reporting Period
This Form 8-K reports the consummation of a business combination on June 9, 2021, between ARYA Sciences Acquisition Corp III ("ARYA") and Nautilus Biotechnology, Inc. ("Old Nautilus"). Upon closing, ARYA domesticated as a Delaware corporation, changed its name to "Nautilus Biotechnology, Inc." ("New Nautilus"), and Old Nautilus became a wholly-owned subsidiary. New Nautilus is a development-stage life sciences company focused on creating a platform technology for quantifying the human proteome. The company has no products available for commercial sale and has not generated revenue since inception.
Key Financial Metrics
Capital Raised and Liquidity:
- PIPE Financing: $200 million raised from PIPE Investors via the purchase of 20,000,000 shares at $10.00 per share.
- Total Proceeds: Approximately $345 million in gross proceeds received from the Business Combination and PIPE Financing.
- Transaction Costs: Approximately $20 million in transaction costs and underwriters' fees.
- Cash Position (Pre-Closing): As of March 31, 2021, Old Nautilus held $67.8 million in cash, cash equivalents, and short-term investments.
- Runway: Management believes current cash resources will fund operations for at least the next 12 months post-closing.
Operating Performance (Three Months Ended March 31, 2021):
- Revenue: $0 (No revenue generated to date).
- Net Loss: $8.4 million.
- Accumulated Deficit: $38.7 million as of March 31, 2021.
- Operating Expenses: Total of $8.4 million, comprised of $4.8 million in Research and Development (R&D) and $3.6 million in General and Administrative (G&A) expenses.
- Cash Flow: Net cash used in operating activities was $6.3 million; net cash provided by investing activities was $23.5 million (primarily from maturities of securities).
Capital Structure (Post-Closing):
- Shares Outstanding: 124,045,255 shares of Common Stock.
- Options Outstanding: 7,106,767 shares subject to options under the 2017 Plan.
- Implied Equity Value: $900 million (basis for option exchanges).
Material Changes Versus Prior Period
Operating Expenses (Three Months Ended March 31, 2021 vs. 2020):
- R&D Expenses: Increased 96% to $4.8 million from $2.5 million, driven by higher salaries, stock-based compensation, and laboratory supplies.
- G&A Expenses: Increased 580% to $3.6 million from $0.5 million, primarily due to increased professional services (audit/legal) and personnel costs.
- Net Loss: Increased 187% to $8.4 million from $2.9 million.
Corporate Status: The company transitioned from a private entity to a public company trading on the Nasdaq under the symbol "NAUT," ceasing to be a shell company.
Guidance, Outlook, and Risks
Commercialization Strategy:
- Phase 1 (Current): Collaboration with biopharma and academic institutions to validate technology. No significant revenue expected.
- Phase 2 (Early Access): Expected to begin no earlier than H2 2022. Limited revenue expected; phase to continue through end of 2023.
- Phase 3 (Broad Launch): Anticipated for end of 2023/beginning of 2024. Material revenue not expected prior to H2 2023.
Management Commentary:
Management expects to continue incurring significant losses for the foreseeable future as it advances R&D and builds commercial infrastructure. The company relies on the successful development of its Nautilus Platform, which remains in the development stage.
Risks and Contingencies:
- Development Risk: The Nautilus Platform is subject to scientific and technical validation; there is no assurance it will be commercially viable.
- Capital Requirements: Substantial additional funding will be required. Failure to raise capital could force delays or elimination of product development.
- Manufacturing: Complex manufacturing requirements for instruments and over 300 reagents pose supply chain and production risks.
- COVID-19: Pandemic-related disruptions have caused supply chain delays (e.g., chip manufacturers) and reduced lab work volume, though the company is monitoring the situation.
Investor Verification Checklist
- Verify the $345 million gross proceeds and the specific allocation of funds post-closing.
- Confirm the timeline for the three-phase commercialization plan, specifically the H2 2023 target for material revenue.
- Review the $38.7 million accumulated deficit and the burn rate relative to the 12-month runway estimate.
- Assess the status of the Nautilus Platform prototype and any recent scientific validation milestones.
- Examine the terms of the Change in Control and Severance Agreements for executive officers, particularly the acceleration of equity vesting.
- Monitor the company's ability to secure manufacturing partners for complex reagents and instruments.